Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
LDP Tax Panel Execs Eye Slight Cut of R&D Tax Deduction Cap
Executive members of the Liberal Democratic Party’s (LDP) tax panel are considering slightly lowering the current deduction ceiling of a special R&D tax credit system for the next fiscal year. The core component of the system is temporarily capped at…
To read the full story
Related Article
- LDP Study Group Shows Sense of Crisis over Reduction of R&D Tax Deduction Cap
December 25, 2014
- FPMAJ “Hasn’t Given Up” on Maintenance of 30% R&D Tax Deduction Cap: Chairman
December 24, 2014
- LDP to Begin Intensive Tax Debate from December 25
December 19, 2014
- JPMA Tones Down Demand on R&D Tax Credit System, Calls for “Maintenance” Instead of “Perpetuation”
October 20, 2014
- New Minister Eager to Keep 30% Deduction Cap for R&D Tax Credit System
September 10, 2014
- MHLW Calls for Maintenance of Current R&D Tax Credit Limit
August 27, 2014
- Govt Tax Panel Proposes Maintenance of Scaled-Down R&D Tax Credits
June 30, 2014
REGULATORY
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…